International Transaction Journal of Engineering, Management, & Applied Sciences & Technologies


:: International Transaction Journal of Engineering, Management, & Applied Sciences & Technologies TuEngr+QR-Code

ISSN 2228-9860
eISSN 1906-9642


Vol.12(8) (2021)


  1. Bandeira, IC, et al. Chronic inflammatory state in sickle cell anemia patients is associated with HBB* S haplotype. Cytokine. 2014. 65(2):217-221.
  2. El-Kader, SMA and Al-Shreef, FM. Impact of aerobic exercises on selected inflammatory markers and immune system response among patients with sickle cell anemia in asymptomatic steady state. African Health Sciences. 2018. 18(1):111-119.
  3. Rees, DC, Williams, TN, Gladwin, MT. Sickle-cell disease. The Lancet. 2010; 376(9757):2018-2031.
  4. Torres, LS, et al. Inflammation in sickle cell disease: differential and down-expressed plasma levels of annexin A1 protein. PLoS One. 2016;11(11):e0165833.
  5. Ren, G, Roberts, AI, Shi, Y. Adhesion molecules: key players in Mesenchymal stem cell-mediated immunosuppression. Cell adhesion & migration. 2011;5(1):20-22.
  6. Van de Stolpe, A, der Saag, V. Intercellular adhesion molecule-1. Journal of molecular medicine. 1996;74(1):13-33.
  7. Ley, K, Huo, Y. VCAM-1 is critical in atherosclerosis. The Journal of clinical investigation, 2001;107(10):1209-1210.
  8. Kansas, GS. Selectins and their ligands: current concepts and controversies. 1996.
  9. Hassan, AA, et al. Selectins: An Important Family of Glycan-Binding Cell Adhesion Molecules in Ovarian Cancer. Cancers. 2020;12(8):2238.
  10. Zarbock, A, et al. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood. 2011;118(26):6743-6751.
  11. Tedder, T, et al. The selectins: vascular adhesion molecules. The FASEB Journal. 1995;9(10):866-873.
  12. Antwi-Boasiako, C, et al. Levels of Soluble Endothelium Adhesion Molecules and Complications among Sickle Cell Disease Patients in Ghana. Diseases. 2018;6(2):29.
  13. Canalli, AA, et al. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica. 2008;93(4):605-609.
  14. Ahmed, AE, et al. Health-related quality of life in patients with sickle cell disease in Saudi Arabia. Health and quality of life outcomes. 2015;13(1):183.
  15. Zaini, R. Sickle-cell anemia and consanguinity among the Saudi Arabian population. Arch Med. 2016;8(3):3-15.
  16. Khan, S, et al. Use of rapid biomarking technique to estimate oxidative stress in course dependent children with sickle cell disease in Saudi Arabia.
  17. Nur, E, et al. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. American journal of hematology. 2011;86(6):484-489.
  18. Klings, ES, Farber, HW. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respiratory Research. 2001;2(5):1-6.
  19. Neto, PFT, et al. Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Cear?, Brazil. Revista brasileira de hematologia e hemoterapia. 2011;33(3):207-210.
  20. Obeagu, EI, Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
  21. Mack, AK, Kato, GJ. Sickle cell disease and nitric oxide: a paradigm shift? The international journal of biochemistry & cell biology. 2006;38(8):1237-1243.
  22. Makis, A, Hatzimichael, E, Bourantas, K. The role of cytokines in sickle cell disease. Annals of hematology. 2000; 79(8):407-413.
  23. Conran, N, et al. Increased levels of soluble ICAM?1 in the plasma of sickle cell patients are reversed by hydroxyurea. American journal of hematology. 2004;76(4):343-347.
  24. Serjeant, GR. Sickle-cell disease. The Lancet. 1997;350(9079):725-730.
  25. Frenette, PS. Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirculation. 2004;11(2):167-177.
  26. Platt, OS, et al. Mortality in sickle cell disease--life expectancy and risk factors for early death. New England Journal of Medicine. 1994;330(23):1639-1644.
  27. Vercellotti, GM, Belcher, JD. Not simply misshapen red cells: multimolecular and cellular events in sickle vaso-occlusion. The Journal of clinical investigation. 2014;124(4):1462-1465.
  28. Lawrence, MB, and Springer, TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65(5):859-873.
  29. Telen, MJ. Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors. Hematology/Oncology Clinics. 2014;28(2):341-354.
  30. Ley, K. et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature Reviews Immunology. 2007;7(9):678-689.
  31. Kaul, DK, Hebbel, RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. The Journal of clinical investigation. 2000;106(3):411-420.
  32. Frenette, PS, et al. P-selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. The Journal of experimental medicine. 2000;191(8):1413-1422.
  33. Turhan, A, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proceedings of the National Academy of Sciences. 2002;99(5):3047-3051.
  34. Zennadi, R, et al. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood. 2008;112(8):3474-3483.
  35. Wood, K, et al. Differential expression of E-and P-selectin in the microvasculature of sickle cell transgenic mice. Microcirculation. 2004;11(4):377-385.
  36. Mohan, JS, et al. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation. Blood coagulation & fibrinolysis. 2005;16(3):209-214.
  37. Matsui, NM, et al. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001; 98(6):1955-1962.
  38. Solovey, AA, et al. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood, The Journal of the American Society of Hematology. 2001;97(7):1937-1941.
  39. Barinaga, M. Mutant mice mimic human sickle cell anemia. Science. 1997;278(5339):803-804.
  40. Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatric pathology & molecular medicine. 2001;20(1):47-72.
  41. Kato, GJ, et al. Levels of soluble endothelium?derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British journal of haematology. 2005;130(6):943-953.
  42. Diop, S, et al. New results in clinical severity of homozygous sickle cell anemia in Dakar, Senegal. Hematology and cell therapy. 1999;41(5):217-221.
  43. Dworkis, DA, et al. Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. American journal of hematology. 2011;86(2):220.
  44. Cerqueira Sr BA, et al. Adhesion Molecules Interaction with Markers of Lipid Metabolism, Hemolysis, Endothelial Dysfunction and Medical Histories Among Steady-State Sickle Cell Anemia Patients. Blood. 2009;114(22):2553.
  45. Kanavaki, I, et al. Adhesion molecules and high?sensitivity C?reactive protein levels in patients with sickle cell beta?thalassaemia. European journal of clinical investigation. 2012;42(1):27-33.
  46. Blum, A, et al. Endothelial function in patients with sickle cell anemia during and after sickle cell crises. Journal of thrombosis and thrombolysis. 2005;19(2):83-86.
  47. Hubbard, AK, Rothlein, R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free radical biology and medicine. 2000;28(9):1379-1386.
  48. Makis, AC, et al. C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease. Archives of Internal Medicine. 2006;166(3):366-368.
  49. Gambero, S, et al. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. European journal of haematology. 2007;78(2):144-151.
  50. Hillery, CA, et al. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. British Journal of Haematology: RED CELLS. 2000;109(2):322-327.51.
  51. Lebensburger JD, Howard T, Hu Y, Pestina TI, Gao G, Johnson M, Zakharenko SS, Ware RE, Tuomanen EI, Persons DA, Rosch JW. Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood, The Journal of the American Society of Hematology. 2012;119(8):1915-21.
  52. Maugeri N, Giordano G, Petrilli MP, Fraticelli V, De Gaetano G, Cerletti C, Storti S, Donati MB. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?. Journal of Thrombosis and Haemostasis. 2006;4(12):2593-8.

Other issues:


Call-for-Scientific Papers
Call-for-Research Papers: ITJEMAST invites you to submit high quality papers for full peer-review and possible publication in areas pertaining engineering, science, management and technology, especially interdisciplinary/cross-disciplinary/multidisciplinary subjects.

To publish your work in the next available issue, your manuscripts together with copyright transfer document signed by all authors can be submitted via email to Editor @ (no space between). (please see all detail from Instructions for Authors)

Publication and peer-reviewed process:
After the peer-review process (4-10 weeks), articles will be on-line published in the available next issue. However, the International Transaction Journal of Engineering, Management, & Applied Sciences & Technologies cannot guarantee the exact publication time as the process may take longer time, subject to peer-review approval and adjustment of the submitted articles.